Myelosuppression, a reduction in blood cells produced by the bone marrow, is common in cancer patients and can have a tremendous physical, emotional and financial impact. Symptoms of fatigue, the development of infections and bleeding can seriously affect quality of life. Dose reductions and treatment delays may affect treatment response and long-term survival, and healthcare costs related to complications of myelosuppression place a significant burden on society. Myelosuppression most commonly occurs as a side-effect of cancer treatments such as chemotherapy, but can be related to other conditions associated with cancer as well. Several pharmaceutical agents are now available to assist in the management of myelosuppression, and more are being evaluated in clinical trials that have the potential to reduce the risk of cancer treatments. That said, an awareness of the symptoms of anemia, neutropenia and thrombocytopenia, potential complications related to these diagnoses, and conservative management modalities should remain at the forefront in clinical repertoire.
Covid-19 Scenario analysis:
The Covid outbreak across the world has landed cancer patients in grave danger. Worried about their low immunity levels, leading hospitals and research centres are advising cancer patients to remain at home till Covid infections die out. Deferment of surgeries, radiation and chemotherapy sessions have messed up the treatment schedules of many cancer patients across the globe. Patients who are undergoing cancer treatment may have low immunity, and are more susceptible to catching the infection. And if it does, it’ll be very fatal for the patient. So Doctors taking all precautions to keep them safe – at least from Covid. Myelosuppression leads to decreased blood cells production as a result of reduced activity of bone marrow. This may cause decrease in all types of blood cells such as red blood cells (RBCs), white blood cells (WBCs) and platelets or any one hence the immunity of the Cancer patients needs to be driven up by giving them the required treatment hence the market is steady but might have some inconvenience because of supply and manufacturing being low during the pandemic.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:
Drivers:
Rising prevalence of cancer:
The global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease. Worldwide, the total number of people who are alive within 5 years of a cancer diagnosis, called the 5-year prevalence, is estimated to be 43.8 million. The increasing cancer burden is due to several factors, including population growth and ageing as well as the changing prevalence of certain causes of cancer linked to social and economic development. This is particularly true in rapidly growing economies, where a shift is observed from cancers related to poverty and infections to cancers associated with lifestyles more typical of industrialized countries. Rising prevalence of cancer worldwide will substantially augment the growth of chemotherapy-induced myelosuppression treatment market in the coming years. According to the World Health Organization, cancer was responsible for around 9.6 million deaths worldwide. Around 70% of the deaths were reported in low- and middle-income countries. Adoption of unhealthy lifestyle, excessive consumption of tobacco and alcohol and changing environmental factors have largely contributed to the increasing incidence of cancer. Thus, aforementioned factors will spur the growth of the market.
Increased strain on Iron supplement therapy:
Growing emphasis on the research and development of drugs and therapies for chemotherapy-induced myelosuppression treatment in conditions such as neutropenia, anaemia and thrombocytopenia, is expected to create significant growth opportunities in the chemotherapy-induced myelosuppression treatment market. Both oral and IV iron supplementation may be considered to improve anaemia. Because iron supplementation functions at the level of formation of blood cells, it may take several weeks to restore a normal haemoglobin level after therapy. Oral supplements are best taken with an empty stomach, yet some people are unable to tolerate this due to abdominal discomfort. Milk and antacids can interfere with absorption as well. If oral supplementation is not tolerated, IV injections of iron may be used.
Restrains:
Agents are quite costly in addition to carrying potential side-effects, The European Society for Medical Oncology (ESMO) has devised clinical recommendations on when they should be used. According to ESMO, prophylactic use should be limited to patients in whom the risk of febrile neutropenia is greater than 20%, special circumstances are present, or if a chemotherapy dose reduction or delay would be detrimental to outcome.
Special circumstances they cite include a diagnosis of HIV, or when chemotherapy is given as a potentially curative therapy (rather than palliative). For treatment, the use of these agents should be considered in settings of increased morbidity and mortality, such as sepsis, prolonged neutropenia and tissue infections. Common side-effects of Iron therapy include a metallic taste, flushing, myalgia and arthralgia, and the potential for allergic reactions.
Also, loss of patent exclusivity and intense competition may hinder the market growth. Extensive drug pipeline and focus of pharmaceutical companies on development of safe and efficient chemotherapy-induced myelosuppression treatment drugs will bring new growth opportunities for market players over the forecast period.
Key benefits of the report:
- This study presents the analytical depiction of the global Chemotherapy-induced myelosuppression treatment Market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Chemotherapy-induced myelosuppression treatment Market share.
- The current market is quantitatively analyzed to highlight the global Chemotherapy-induced myelosuppression treatment Market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global Chemotherapy-induced myelosuppression treatment Market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Chemotherapy-induced myelosuppression treatment Market research report:
- What are the leading market players active in the Chemotherapy-induced myelosuppression treatment Market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in taking further strategic steps?
Chemotherapy-Induced Myelosuppression Treatment Market Report Highlights
| Aspects | Details |
 By Indication Type |
|
 By Drug Class |
|
 By End User |
|
 By Region |
|
 Key Market Players | Pfizer Inc, Novartis AG, Partner Therapeutics, Inc, Mission Pharmacal Company, Dova Pharmaceuticals, Amgen Inc, Teva Pharmaceutical Industries Ltd, Services, LLC (Johnson & Johnson), Mylan NV |
 | Myelo Therapeutics, Astrazenca Plc, Bristol Myers Squibb |
Loading Table Of Content...
